Tatva Chintan Pharma Chem Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹131Cr
- +52.3% YoY
- +5.6% QoQ
- Net profit
- ₹15Cr
- Q3 FY25: ₹0 Cr
- +50% QoQ
- Margin
- 19%
- +11 pp YoY
- +1 pp QoQ
Guidance rank: #32 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Tatva Chintan Pharma Chem Ltd Q3 FY26 key numbers
- Revenue
- Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products.
As stated in Tatva Chintan Pharma Chem Ltd's Q3 FY26 earnings call transcript · published 8 Aug 2026. Reported figures, not investment advice.
The short version
Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.
From Tatva Chintan Pharma Chem Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products.
- New Jolva plant targeting new agro products and expansion, contributing significantly from late 2027.
- Pharma & Agro new intermediates (3 each) expected to contribute INR 200-250 crores additional revenue in calendar year 2027, ramping up from current sales base.
- SDA segment projected to grow 25-30% in 2026 with capacity utilization around 55%, driven by Euro 7 norm demand surge starting 2027.
- Semiconductor chemicals expected to reach full commercialization around 2028 with very large volume potential.
2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.
- Dahej plant: Recent capex of ~INR 100 crores focused mostly on utilization expansion, optimization, and operational excellence rather than capacity increase.
- Jolva plant expected commissioning: Around September-October 2027, adding new products and revenue streams.
2 more points from Tatva Chintan Pharma Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tatva Chintan has onboarded two customers for the Structured Directing Agents (SDA) segment; one is in final contract signing and expected to start commercial supplies around August 2026.
- The second customer's negotiations are ongoing, with commercialization anticipated in the second half of the current calendar year.
- The Semiconductor Chemicals segment is in early stages; the company will execute its first plant trial order in the current quarter, with gradual full commercialization expected.
- The new Jolva plant, targeted for commissioning around September-October 2027, is expected to support new agro products and expanded existing product lines.
2 more points from Tatva Chintan Pharma Chem Ltd's call on order book
Create a free account to keep reading this call
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Tatva Chintan Pharma Chem Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 131 | 86 | +52.3% | 124 | +5.6% |
| Operating profit (EBITDA) | 25 | 7 | +257.1% | 22 | +13.6% |
| Operating margin | 19% | 8% | +11 pp | 18% | +1 pp |
| Profit before tax | 18 | -0 | — | 14 | +28.6% |
| Net profit (PAT) | 15 | 0 | — | 10 | +50% |
| EPS (₹) | 6.49 | 0.06 | +10716.7% | 4.24 | +53.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q3 FY26 results?
Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
